CR Bard completes MedChem Products takeover:
This article was originally published in Clinica
Executive Summary
CR Bard has completed the takeover of MedChem Products, announced in May (see Clinica No 657, p 11). MedChem shareholders will receive one Bard share per 3.25 MedChem shares. MedChem's Gesco line of vascular access catheters will become part of Bard Access Systems division, headquartered in Salt Lake City, Utah. MedChem Products will retain the haemostasis and wound closure products and operate as a new Bard division with headquarters in Woburn, Massachusetts.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.